Xpovio, Nexpovio (selinexor) is a small molecule pharmaceutical. Selinexor was first approved as Xpovio on 2019-07-03. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target exportin-1. Xpovio's patents are valid until 2035-08-14 (FDA).
|Drug Class||Exportin 1 inhibitors|